IP Library › Granted Patent US 10,287,301
Granted Patent B2
US 10,287,301 · App. 16/010,081 · Granted May 14, 2019

Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders

Inventors: Jason Allan Wiles (Madison, CT); Avinash S. Phadke (Branford, CT); Milind Deshpande (Madison, CT); Atul Agarwal (Hamden, CT); Dawei Chen (Guilford, CT); Venkat Rao Gadhachanda (Hamden, CT); Akihiro Hashimoto (Branford, CT); Godwin Pais (Hamden, CT); Qiuping Wang (Bethany, CT); Xiangzhu Wang (Branford, CT)
Assignee: Achillion Pharmaceuticals, Inc.
C07D513/04C07D401/14C07D403/06C07D403/14C07D405/14C07D409/14C07D413/14C07D417/14C07D471/04C07D487/04C07D493/04C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,287,301
App. No.
16/010,081
Granted
May 14, 2019
Kind
B2
Abstract

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Claims (20)

1. A compound of structure:

or a pharmaceutically acceptable salt thereof.

2. A compound of structure:

3. A pharmaceutical composition comprising a compound of structure:

or a pharmaceutically acceptable salt thereof; in a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3 for the treatment of a human.

5. The pharmaceutical composition of claim 4 , wherein the composition is for oral administration.

6. The pharmaceutical composition of claim 4 , wherein the composition is for topical administration.

7. The pharmaceutical composition of claim 4 wherein the composition is for ocular delivery.

8. The pharmaceutical composition of claim 4 , wherein the composition is for intravitreal delivery.

9. The pharmaceutical composition of claim 4 , wherein the composition is for subchoroidal delivery.

10. The pharmaceutical composition of claim 4 , wherein the composition is for suprachoroidal delivery.

11. The pharmaceutical composition of claim 4 , wherein the composition is in a tablet dosage form.

12. The pharmaceutical composition of claim 4 , wherein the composition is in a capsule dosage form.

13. The pharmaceutical composition of claim 4 , wherein the composition is for intravenous administration.

14. The pharmaceutical composition of claim 4 , wherein the composition is for transdermal administration.

15. The pharmaceutical composition of claim 4 , wherein the composition is for parenteral administration.

16. The pharmaceutical composition of claim 4 to treat atypical hemolytic uremic syndrome.

17. The pharmaceutical composition of claim 4 to treat paroxysmal nocturnal hemoglobinuria.

18. The pharmaceutical composition of claim 4 to treat C3 glomerulonephritis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2020
From: WILES, JASON ALLAN; PHADKE, AVINASH S.; DESHPANDE, MILIND; AGARWAL, ATUL; CHEN, DAWEI; GADHACHANDA, VENKAT RAO; HASHIMOTO, AKIHIRO; PAIS, GODWIN; WANG, QIUPING; WANG, XIANGZHU
To: ACHILLION PHARMACEUTICALS, INC.
Reel/Frame 052589/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2018
From: DESHPANDE, MILIND; PHADKE, AVINASH S.; WILES, JASON ALLAN; PAIS, GODWIN; HASHIMOTO, AKIHIRO; GADHACHANDA, VENKAT RAO; WANG, QIUPING; CHEN, DAWEI; WANG, XIANGZHU; AGARWAL, ATUL
To: ACHILLION PHARMACEUTICALS, INC.
Reel/Frame 046806/0329 →
Continuity (3)
Continuation 15247399 · Aug 25, 2016
Provisional Application 62209972 · Aug 26, 2015
Related Publication 20180305375A1 · Oct 25, 2018
Cited By (4)
US 12,239,645 US 12,297,205 US 12,338,230 US 12,479,856